Advertisement
Screener

HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) Graph

HRMY Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $261.28M; Cost of revenue $63.20M; Research and development $46.60M; Operating expenses $108.77M.
  • 2026-03-31: Revenue $215.39M; Cost of revenue $44.51M; Research and development $69.38M; Operating expenses $133.58M.
  • 2025-12-31: Revenue $243.78M*; Cost of revenue $68.55M*; Research and development $49.93M*; Operating expenses $136.67M*.
  • 2025-09-30: Revenue $239.46M; Cost of revenue $59.65M; Research and development $54.96M; Operating expenses $114.32M.

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

HRMY revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Rare NeurologicalDiseases Segment$261.28MRevenue$261.28MCost of revenue$63.20MGross profit$198.08MOperating expenses$108.77MOperating income$89.32MOther income, net-$53.00KResearch & development$46.60MPre-tax income$93.26MIncome tax$17.83MNet income$75.43M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$261.28M$63.20M$46.60M$108.77M$17.83M$75.43M
2026-03-31$215.39M$44.51M$69.38M$133.58M$7.20M$32.49M
2025-12-31$243.78M*$68.55M*$49.93M*$136.67M*$18.27M*$22.49M*
2025-09-30$239.46M$59.65M$54.96M$114.32M$16.63M$50.87M
2025-06-30$200.49M$38.15M$50.16M$114.16M$9.86M$39.78M
2025-03-31$184.73M$31.99M$34.54M$96.49M$11.62M$45.56M
2024-09-30$186.04M$42.78M$25.39M$81.55M$16.08M$46.09M
2024-06-30$172.81M$32.14M$63.58M$119.31M$10.10M$11.59M
2024-03-31$154.62M$27.48M$22.19M$75.10M$13.45M$38.33M
2023-09-30$160.27M$32.30M$17.50M$63.46M$13.37M$38.46M
2023-06-30$134.22M$25.01M$14.97M$62.31M$9.79M$34.30M
2023-03-31$119.13M$20.78M$13.29M$57.92M$8.29M$29.48M
2022-09-30$117.21M$22.96M$40.55M$82.35M-$79.98M$87.94M
2022-06-30$107.03M$18.92M$12.67M$54.99M$5.70M$23.53M
2022-03-31$85.31M$14.72M$7.58M$43.04M$1.90M$21.48M
2021-09-30$80.73M$14.60M$11.74M$45.08M-$902.00K-$9.62M
2021-06-30$73.82M$12.69M$6.50M$37.82M$1.97M$14.12M
2021-03-31$59.67M$10.41M$4.68M$34.73M(m)$7.39M
2020-09-30$45.61M$7.89M$4.23M$27.34M(m)$1.91M
2020-06-30$38.01M$6.46M$4.17M$24.24M(m)-$27.00K
2020-03-31$19.84M$3.47M$3.43M$25.98M(m)-$38.62M
2019-09-30(m)(m)$4.34M$29.80M(m)-$31.90M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$476.67M$107.71M$115.98M$242.35M$25.03M$107.92M
2025-06-30$385.22M$70.15M$84.70M$210.65M$21.48M$85.34M
2024-06-30$327.43M$59.63M$85.77M$194.41M$23.55M$49.92M
2023-06-30$253.34M$45.79M$28.26M$120.23M$18.09M$63.78M
2022-06-30$192.34M$33.64M$20.25M$98.03M$7.60M$45.02M
2021-06-30$133.50M$23.10M$11.18M$72.55M$1.97M$21.50M
2020-06-30$57.84M$9.93M$7.60M$49.07M(m)-$38.65M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$624.68M$129.80M$139.66M$324.97M$38.10M$136.20M
2024-09-30$513.47M$102.41M$111.16M$275.96M$39.63M$96.02M
2023-09-30$413.61M$78.08M$45.76M$183.69M$31.46M$102.25M
2022-09-30$309.55M$56.60M$60.79M$180.38M-$72.38M$132.96M
2021-09-30$214.23M$37.70M$22.92M$117.63M$1.07M$11.88M
2020-09-30$103.45M$17.82M$11.83M$76.41M(m)-$36.74M
2019-09-30(m)(m)$62.32M$112.21M(m)-$115.54M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$868.45M$198.34M$189.59M$461.64M$56.38M$158.69M
2024-12-31$714.73M$156.81M$145.82M$367.09M$46.31M$145.49M
2023-12-31$582.02M$121.24M$76.06M$268.76M$44.54M$128.85M
2022-12-31$437.86M$83.48M$70.89M$234.19M-$76.78M$181.47M
2021-12-31$305.44M$55.52M$30.37M$162.39M$2.83M$34.60M
2020-12-31$159.74M$27.74M$19.45M$115.02M(m)-$36.94M
2019-12-31$6.00M$1.58M$69.59M$150.32M(m)-$151.98M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
uniQure N.V. (QURE)$2.416B-4.93
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Immunome Inc. (IMNM)United States$2.538B-9.45
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Zai Lab Ltd (ZLAB)$2.241B-113.34